Biodel Prices Public Offering of Common Stock
June 19, 2013 08:30 ET
|
Biodel Inc.
DANBURY, Conn., June 19, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today announced the pricing of an underwritten public offering of 4,482,760 shares of its common stock at a public offering...
Biodel Announces Proposed Public Offering of Common Stock
June 18, 2013 16:01 ET
|
Biodel Inc.
DANBURY, Conn., June 18, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today announced that it is offering to sell, subject to market and other conditions, shares of its common stock in an...
Biodel Announces Data Presentations at American Diabetes Association Annual Meeting
June 17, 2013 06:00 ET
|
Biodel Inc.
- Selected by ADA for late breaking presentation of Biodel's proprietary ultra-rapid-acting analog formulations
- Presentation of data for new class of concentrated ultra-rapid-acting...
Biodel Announces Development Plans to Commercialize Glucagon Rescue Product Candidate for the Treatment of Severe Hypoglycemia
June 06, 2013 06:00 ET
|
Biodel Inc.
- New Drug Application submission anticipated in 2015
- Acquired worldwide exclusivity to proprietary dual-chamber device
DANBURY, Conn., June 6, 2013 (GLOBE NEWSWIRE) -- Biodel Inc....
Biodel Reports Second Quarter Fiscal Year 2013 Financial Results
May 08, 2013 07:30 ET
|
Biodel Inc.
DANBURY, Conn., May 8, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today reported financial results for the second fiscal quarter ended March 31, 2013.
Portfolio highlights since last fiscal...
Biodel to Report Second Quarter Fiscal Year 2013 Financial Results on May 8, 2013
May 06, 2013 06:50 ET
|
Biodel Inc.
DANBURY, Conn., May 6, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) will issue its second quarter fiscal year 2013 financial results on May 8, 2013. Following the release of the company's...
Biodel Completes Enrollment in Phase 2 Clinical Trial of Ultra-Rapid-Acting Insulin Candidate BIOD-123 for the Treatment of Diabetes
March 28, 2013 06:00 ET
|
Biodel Inc.
DANBURY, Conn., March 28, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today announced the completion of patient enrollment in a Phase 2 clinical study of ultra-rapid-acting prandial insulin...
Biodel Reports First Quarter Fiscal Year 2013 Financial Results
February 12, 2013 16:30 ET
|
Biodel Inc.
DANBURY, Conn., Feb. 12, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today reported financial results for the first fiscal quarter ended December 31, 2012.
Highlights since first fiscal...
Biodel to Report First Quarter Fiscal Year 2013 Financial Results on February 12, 2013
February 06, 2013 06:00 ET
|
Biodel Inc.
DANBURY, Conn., Feb. 6, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) will issue its first quarter fiscal year 2013 financial results on February 12, 2013. Following the release of the company's...
Biodel to Present at 2013 BIO CEO and Investor Conference
February 05, 2013 06:00 ET
|
Biodel Inc.
DANBURY, Conn., Feb. 5, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) announced today that management will be presenting an overview of the company's technologies, development programs, and...